Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the human insulin inhalation powder plus oral anti-hyperglycemic medication with injected insulin (neutral protamine hegedom insulin) plus oral anti-hyperglycemic medication on lowering the…
- Trial name
- NCT00490854
- Testing
- Human Insulin Inhalation Powder, Neutral protamine hagedorn insulin
- Where
- 13 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type II
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
- Trial name
- NCT00947557
- Testing
- Dutogliptin
- Where
- 147 sites in United States, Belarus and 6 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®
This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.
- Trial name
- EVIDENCE (NCT00658099)
- Testing
- insulin detemir, insulin NPH
- Where
- Romania
- Volunteers
- 699 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes
The study will demonstrate the effect of 24 weeks of treatment with vildagliptin compared to placebo on insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) treated with metformin, assessed as glucose Rd (rate of…
- Trial name
- NCT01356381
- Testing
- Vildagliptin
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2…
- Trial name
- NCT02229396
- Testing
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Where
- 133 sites in United States, Hungary and 4 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Hypertension, Type 2 Diabetes
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit.
- Trial name
- NCT00803660
- Where
- 19 sites in Vietnam
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination)…
- Trial name
- NCT07552389
- Testing
- Test group, Exploratory test group, Control group 1
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
The primary purpose of this study is to assess the renal protective effect of ipragliflozin in combination with metformin on the percent change of UACR from baseline to 24 weeks against glimepiride in combination with metformin…
- Trial name
- NCT03118713
- Testing
- metformin, ipragliflozin, glimepiride
- Where
- 8 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Astellas Pharma Korea, Inc.
Drug Interaction
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
The purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of Dorzagliatin.
- Trial name
- NCT04080596
- Testing
- Dorzagliatin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus…
- Trial name
- EDITION III (NCT01676220)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 217 sites in United States, Bulgaria and 14 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus.
- Trial name
- NCT04235959
- Testing
- Tirzepatide
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy
This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar compared with placebo when added to a sulfonylurea monotherapy or sulfonylurea plus metformin…
- Trial name
- NCT01691989
- Testing
- aleglitazar
- Where
- 28 sites in United States, Argentina and 3 more
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung
Randomized, unblinded, controlled, two arms parallel group, prospective intervention study
- Trial name
- NCT05657769
- Testing
- Medwell Preventive Care Application, Manual Records
- Where
- Indonesia
- Volunteers
- 160 people
- Sponsor
- PT Bio Farma
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.
Diabetes Mellitus Type 2
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with…
- Trial name
- NCT01042769
- Testing
- Aleglitazar
- Where
- 810 sites in United States, Argentina and 25 more
- Volunteers
- 7,226 people
- Sponsor
- Hoffmann-La Roche
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
- Trial name
- NCT00673231
- Testing
- Dapagliflozin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after…
- Trial name
- NCT01372163
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes
Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of long-term use of Sonias Combination Tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT02098733
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 1,168 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.